A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies

Background MET is a tyrosine kinase receptor involved in the regulation of cell proliferation and migration. Reported here are the phase I dose-escalation results for LY2875358, a monoclonal antibody against MET, in Japanese patients with advanced malignancies. Methods The study comprised a 3 + 3 do...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoh, Kiyotaka, Doi, Toshihiko, Ohmatsu, Hironobu, Kojima, Takashi, Takahashi, Hideaki, Zenke, Yoshitaka, Wacheck, Volker, Enatsu, Sotaro, Nakamura, Takashi, Turner, Kellie, Uenaka, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007274/
https://www.ncbi.nlm.nih.gov/pubmed/27422720
http://dx.doi.org/10.1007/s10637-016-0370-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007274/
https://www.ncbi.nlm.nih.gov/pubmed/27422720
http://dx.doi.org/10.1007/s10637-016-0370-7

Ejemplares similares